An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells

Abstract Background Antisense oligonucleotide (ASO) medicine for clinical applications has been becoming a reality. We previously developed a gapmer ASO targeting Ser/Arg repetitive matrix 4 (SRRM4) that is abnormally expressed in small cell lung cancer (SCLC). However the detailed mechanism of ASO...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Misa Yoshida, Chihiro Oda, Keishiro Mishima, Itsuki Tsuji, Satoshi Obika, Masahito Shimojo
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-01-01
Serie:	Cancer Cell International
Soggetti:	REST/NRSF Small cell lung cancer SCLC Antisense oligonucleotide Gapmer SRRM4
Accesso online:	https://doi.org/10.1186/s12935-022-02842-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!